## IN THE CLAIMS

Please amend claims 21, 30, and 31 as follows.

This listing of the claims replaces all prior versions of the claims in the application.

1-20. (Canceled)

- 21. (Currently Amended) An isolated polypeptide selected from the group consisting of:
- a) a polypeptide comprising an amino acid sequence of SEQ ID NO:1,
- a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:1, said polypeptide having alcohol dehydrogenase activity,
- c) a biologically active fragment of a polypeptide having an amino acid sequence of SEQ ID NO:1, said fragment having alcohol dehydrogenase activity, and
- an immunogenic fragment of a polypeptide consisting of an amino acid sequence of SEQ ID NO:1, wherein said fragment comprises at least 15 contiguous amino acid residues of SEQ ID NO:1 and generates an antibody that specifically binds to a polypeptide comprising an amino acid sequence of SEQ ID NO:1.
- 22. (Previously Presented) An isolated polypeptide of claim 21 comprising an amino acid sequence of SEQ ID NO:1.
- 23. (Previously Presented) An isolated polynucleotide encoding a polypeptide of claim 21.
- 24. (Previously Presented) An isolated polynucleotide encoding a polypeptide of claim 22.
- 25. (Previously Presented) An isolated polynucleotide of claim 24 comprising a polynucleotide sequence of SEQ ID NO:3.

26. (Previously Presented) A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 23.

- 27. (Previously Presented) A cell transformed with a recombinant polynucleotide of claim 26.
- 28. (Previously Presented) A method of producing a polypeptide of claim 21, the method comprising:
  - a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 21, and
  - b) recovering the polypeptide so expressed.
- 29. (Previously Presented) A method of claim 28, wherein the polypeptide comprises an amino acid sequence of SEQ ID NO:1.
- 30. (Currently Amended) An isolated polynucleotide selected from the group consisting of:
  - a) a polynucleotide comprising a polynucleotide sequence of SEQ ID NO:3,
  - b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence of SEQ ID NO:3, said polynucleotide encoding a polypeptide having alcohol dehydrogenase activity,
  - c) a polynucleotide complementary to a polynucleotide of a),
  - d) a polynucleotide complementary to a polynucleotide of b), and
  - e) an RNA equivalent of a)-d).
- 31. (Currently Amended) An isolated polynucleotide comprising consisting of at least 60 contiguous nucleotides of a polynucleotide of SEQ ID NO:3.

119229 3 09/743,752

32. (Withdrawn) A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 30, the method comprising:

- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
- b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
- 33. (Withdrawn) A method of claim 32, wherein the probe comprises at least 60 contiguous nucleotides.
- 34. (Withdrawn) A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 30, the method comprising:
  - a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
  - b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
- 35. (Withdrawn) A composition comprising a polypeptide of claim 21 and a pharmaceutically acceptable excipient.
- 36. (Withdrawn) A composition of claim 35, wherein the polypeptide comprises an amino acid sequence of SEQ ID NO:1.
- 37. (Withdrawn) A method for treating a disease or condition associated with decreased expression of functional ScRM, comprising administering to a patient in need of such treatment the composition of claim 35.

38. (Withdrawn) A method of screening for a compound that specifically binds to the polypeptide of claim 21, the method comprising:

- a) combining the polypeptide of claim 21 with at least one test compound under suitable conditions, and
- b) detecting binding of the polypeptide of claim 21 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 21.
- 39. (Withdrawn) A method of screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 25, the method comprising:
  - a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
  - b) detecting altered expression of the target polynucleotide, and
  - c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.
- 40. (Withdrawn) A method of assessing toxicity of a test compound, the method comprising:
  - a) treating a biological sample containing nucleic acids with the test compound,
  - b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 30 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 30 or fragment thereof,
  - c) quantifying the amount of hybridization complex, and
  - d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

41. (Withdrawn) A microarray wherein at least one element of the microarray is a polynucleotide of claim 23.

- 42. (Withdrawn) A method of generating an expression profile of a sample which contains polynucleotides, the method comprising:
  - a) labeling the polynucleotides of the sample,
  - contacting the elements of the microarray of claim 41 with the labeled
    polynucleotides of the sample under conditions suitable for the formation of a
    hybridization complex, and
  - c) quantifying the expression of the polynucleotides in the sample.
- 43. (Withdrawn) An isolated antibody which specifically binds to a polypeptide of claim 21.
  - 44. (Withdrawn) The antibody of claim 43, wherein the antibody is:
  - a) a chimeric antibody,
  - b) a single chain antibody,
  - c) a Fab fragment,
  - d) a F(ab')<sub>2</sub> fragment, or
  - e) a humanized antibody.
- 45. (Withdrawn) A composition comprising an antibody of claim 43 and an acceptable excipient.